Graves' Ophthalmopathy (GO) clinical trials at UC Health
1 research study open to eligible people
Showing trials for
ASCEND GO-2: Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )
open to eligible people ages 18 years and up
The purpose of the current study is to assess the efficacy and safety/tolerability of three dose regimens of RVT-1401 in the treatment of active, moderate to severe GO patients. In addition, the study is designed to characterize the effect of RVT-1401 exposure on reduction in anti-TSHR IgG
at UCLA
Last updated: